Effects of acupuncture for nonalcoholic fatty liver disease
A protocol for systematic review and meta-analysis
Xiaoming Zang, MD\textsuperscript{a}, Mi Sun, MD\textsuperscript{a}, Jin Xian, MD\textsuperscript{a}, Huijuan Yu, MD\textsuperscript{a}, Xin Zhang, MD\textsuperscript{a}, Changyun Zhang, MD\textsuperscript{b}, Qiwen Tan, MD\textsuperscript{a,*}

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease, which may develop gradually into nonalcoholic steatohepatitis, liver fibrosis, and cirrhosis. As a classical method of traditional Chinese medicine, acupuncture has been used to treat NAFLD in clinical practice. However, there is no systematic review and meta-analysis of acupuncture on NAFLD. There is an urgent need to evaluate the clinical efficacy of acupuncture for NAFLD.

Methods: We will perform a comprehensive retrieval in the following electronic databases: MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, PubMed, Science Citation Index Expanded (Web of Science), Epistemonikos, China National Knowledge Infrastructure (CNKI) database, Wanfang Data Knowledge Service Platform, Chinese Scientific Journals Database (VIP), Chinese Biomedical Literature Service System (SinoMed), and other databases from their inception to October 2020. We will select the qualified studies for data extraction and assess the quality and risk of bias, independently. The meta-analyses will be conducted by using the RevMan 5.3.

Results: This study will provide a reliable basis for the treatment of NAFLD with acupuncture.

Conclusion: The findings will be an available reference to evaluate whether acupuncture is an effective intervention for patient with NAFLD.

OSF registration number: 10.17605/OSF.IO/VFYXH.

Abbreviations: GRADE = Grading of Recommendations Assessment, Development and Evaluate system, NAFLD = nonalcoholic fatty liver disease, RCT = randomized controlled trials.

Keywords: Nonalcoholic fatty liver disease (NAFLD), acupuncture, protocol, systematic review and meta-analysis.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease associated with obesity, insulin resistance, and dyslipidemia, which may develop gradually into nonalcoholic steatohepatitis, liver fibrosis, and cirrhosis. It has become one of the main causes of cirrhosis and hepatocellular carcinoma in recent years.\textsuperscript{[1]} Moreover, NAFLD is a risk factor for many diseases, including cardiovascular disease,\textsuperscript{[2]} type 2 diabetes mellitus,\textsuperscript{[3]} chronic kidney disease,\textsuperscript{[4]} and cancer.\textsuperscript{[5]} In addition, NAFLD is associated with a high incidence of chronic diseases such as obstructive sleep apnea, polycystic ovarian syndrome, colorectal polyps, osteoporosis, and stroke.\textsuperscript{[6]} Thus, early and appropriate prevention and treatment interventions are needed in the management of NAFLD.

Acupuncture is an ancient Chinese medicine-based approach, which has been widely used for the prevention and treatment of various diseases. As a classical method of traditional Chinese medicine, acupuncture has been applied to treat NAFLD in clinical practice due to its advantages of low cost, few side effects, and simple operation. A clinical study has demonstrated that acupuncture can effectively treat NAFLD and present better therapeutic effect on hepatic fat status, glycolipid metabolism, and insulin resistance.\textsuperscript{[7]} Several experiments conducted in NAFLD models showed that acupuncture could repress the process of NAFLD by inhibiting inflammation, reducing oxidative stress, and promoting lipid metabolism in liver cells.\textsuperscript{[8,9]} Moreover, acupuncture at Zu san li, Guan yuan, and Yong quan could suppress lipid absorption by downregulating the expression of apolipoproteins in the small intestine.\textsuperscript{[10]} Although the proportion of application of acupuncture for NAFLD is increasing, there is no systematic review and meta-analysis of...
acupuncture on NAFLD. Hereby, we will systematically evaluate the clinical efficacy of acupuncture for NAFLD, so as to provide an objective and scientific basis for clinical practice.

2. Objective
This systematic review aims to identify and critically summarize randomized controlled trials (RCTs) of acupuncture for treating NAFLD. A comprehensive understanding of the current level of evidence in this work will provide evidence to judge whether acupuncture is an effective intervention for patient with NAFLD.

3. Methods and analysis

3.1. Study design
This work will be conducted followed the guideline of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) recommendations. We have registered this work at Open Science Framework (OSF, https://osf.io/), an open source project management that helps in the design of studies. The registration DOI of this study is 10.17605/OSF.IO/VPYXH.

3.2. Types of studies
We will include RCTs that used acupuncture or a combination of acupuncture and routine pharmacotherapy as treatment measures. Nonrandomized control studies and observational study will be excluded in the review. Language will be limited to English and Chinese.

3.3. Type of participants
We will include patients with a diagnosis of NAFLD based on liver histology or imaging (ultrasound, computer tomography, magnetic resonance imaging). There will be no limitation about age, gender, region, and other factors.

3.4. Types of interventions
- Experimental intervention: we will only include studies that interventions involved acupuncture alone or combined with other routine pharmacotherapy, as well as those with control groups, which can verify the therapeutic effect of acupuncture.
- Control intervention: trials in which the control group will include no treatment, placebo, exercise intervention, diet intervention, and conventional treatments. Conventional treatments include drugs recommended by the international or domestic authorized clinical guidelines.

3.5. Types of outcome measures
3.5.1. Primary outcomes. The improvement of imaging markers, liver enzymes, serological indexes of hepatic fibrosis, and serum NAFLD liver fat score.

3.5.2. Secondary outcomes. Secondary outcomes include the changes of BMI, insulin levels, lipid profiles, total efficacy rate, and adverse events.

3.6. Search methods for identification of studies
3.6.1. Electronics searches. We will identify trials through systematic searches of the following bibliographic databases: MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, PubMed, Science Citation Index Expanded (Web of Science), Epistemonikos, China National Knowledge Infrastructure (CNKI) database, Wanfang Data Knowledge Service Platform, Chinese Scientific Journals Database (VIP), Chinese Biomedical Literature Service System (SinoMed) from their inception to October 2020. The reference lists of relevant records will also be reviewed to identify potentially eligible trials.

3.6.2. Searching other resources.
- Google scholar and Baidu scholar.
- WHO International Clinical Trial Registry Platform.
- Chinese Clinical Trial Registry (ChiCTR).
- ClinicalTrials.gov.

3.7. Data collection and analysis
3.7.1. Selection of studies. The titles and abstracts of all searched studies will be assessed independently by 2 methodological trained reviewers in accordance with the established selection criteria. We will assess all potentially relevant articles as full-text. Any disagreements generated between the 2 reviewers will be solved through consensus with other authors. A PRISMA flow diagram will be drawn to illustrate the study selection procedure (Fig. 1).

3.7.2. Data extraction and management. Two review authors will independently extract information from all eligible studies. The extracted information will be export to Excel table, which includes the first authors of the article, publication year, interventions in experimental group and control group, time of treatment, sample size, age, gender, outcome indicators, and adverse events. If data are not available from these studies, we will contact the corresponding authors to obtain the information.

3.7.3. Measures of treatment effect. We will use RevMan V5.3 (the Nordic Cochrane Centre, Copenhagen, Denmark) to analyze the data. For dichotomous variables, a risk ratio (RR) with 95% confidence interval (95% CI) will be used for analysis. For continuous outcomes, we will calculate the mean differences (MDs) and the standard mean difference (SMD) with 95% CI to evaluate the treatment effect.

3.7.4. Assessment of risk of bias. Two authors will independently assess risk of bias for each study using the Cochrane Collaboration’s tool. We will evaluate the methodology through 6 items, including performance bias, detection bias, attrition bias, reporting bias, and other sources of bias. The assessment will be classified into 3 levels: “Low risk,” “High risk,” or “Unclear risk.” Any disagreements between the 2 reviewers will be resolved by discussion and consensus among all authors.

3.7.5. Dealing with missing data. When data are not available from the studies, the missing information will be obtained by contacting the corresponding authors. Then, we will perform a sensitivity analysis using imputations of missing outcome data of dichotomous outcomes in best-worse and worse-best case scenarios to assess the potential impact of loss to follow-up.

3.7.6. Assessment of heterogeneity. The Cochrane X² and I² tests will be utilized to assess the statistical heterogeneity of evidence. When P ≥ .1 and I² ≤ 50%, it is considered that there is no statistical heterogeneity or the heterogeneity is small. When
$P < .1$ and $I^2 > 50\%$, the result indicates that there is a statistical heterogeneity.

3.7.7. Data analysis. Review Manager software version 5.3 will be used for data synthesis and analysis. If there is no heterogeneity, the data are synthesized using a fixed effect model. If there is significant heterogeneity, a random effect model is used to analyze.

3.7.8. Sensitivity analysis. We will conduct a sensitivity analysis will be performed to evaluate the robustness of the results. We will remove the low-level quality study one by one and then compile the data to assess the impact of sample size, study quality, statistical method, and missing data on the result of this work.

3.7.9. Assessment of reporting bias. A funnel plot will be drawn to assess the publication bias if we include more than 10 studies. The potential reporting biases will be statistical appraised by the Egger test.[16]

3.7.10. Grading the quality of evidence. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) will be used to assess the quality level of evidence.[17] The assessments of evidence quality will be assorted into “high,” “moderate,” “low,” and “very low” quality.[18]

3.8. Patient and public involvement

Patient and public were not involved in this study.

3.9. Ethics and dissemination

No ethical approval will be required because the data used are not linked to individual patient. The results of this review will be published in a peer-reviewed journal.

---

[Figure 1. Flow chart of study selection.]
4. Discussion
As one of the most common causes of chronic liver disease in many countries worldwide, NAFLD is a condition in which there is accumulation of excess fat in the liver of people who drink little or no alcohol. At present, there is no effective treatment available in the therapy of NAFLD.[19] Thus, it is of significance to seek new therapies for the treatment of NAFLD. Acupuncture has been used to treat NAFLD through regulating lipid metabolism, participating lipid metabolism-related signaling pathways, improving insulin resistance, and increasing the antioxidant levels of liver tissue.[20,21] In this work, we provide a detailed summary of the current evidence related to the efficacy of acupuncture in treating the patients with NAFLD. The results of this review will be useful to clinicians regarding the use of acupuncture in NAFLD treatment.

Author contributions
Conceptualization: Qiwen Tan.
Data curation: Xiaoming Zang, Mi Sun.
Formal analysis: Xiaoming Zang, Mi Sun.
Funding acquisition: Qiwen Tan.
Methodology: Huijuan Yu, Changyun Zhang.
Resources: Xiaoming Zang, Mi Sun, Jin Xian, Huijuan Yu
Software: Xiaoming Zang, Mi Sun
Supervision: Qiwen Tan, Jin Xian, Xin Zhang, Changyun Zhang.
Validation: Xiaoming Zang, Huijuan Yu.
Visualization: Xiaoming Zang, Jin Xian, Xin Zhang.
Writing - original draft: Xiaoming Zang, Mi Sun
Writing – review & editing: Xin Zhang, Changyun Zhang, Qiwen Tan.

References